The CADEUS study:: methods and logistics

被引:17
作者
Depont, F.
Fourrier, A.
Merliere, Y.
Droz, C.
Amouretti, M.
Begaud, B.
Benichou, J.
Moride, Y.
Blin, P.
Moore, N.
机构
[1] Univ Victor Segalen, Dept Pharmacol, F-33076 Bordeaux, France
[2] INSERM, U657, IFR 99, Bordeaux, France
[3] CNAMTS, Serv Projets Informat, Paris, France
[4] CHU Bordeaux, Serv Hepatogastroenterol, Bordeaux, France
[5] Univ Victor Segalen, Bordeaux, France
[6] CHU Rouen, Unite Biostat, Rouen, France
[7] INSERM, U657, Rouen, France
[8] Univ Montreal, Fac Pharm, Montreal, PQ H3C 3J7, Canada
关键词
pharmacoepidemiology; drug utilization; healthcare systems; databases; questionnaires; response rate; cox-2; inhibitor; non-steroidal anti-inflammatory drugs;
D O I
10.1002/pds.1348
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Purpose At the request of the French Health authorities, a study called CADEUS (COX-2 inhibitors and NSAIDs: description of users) aimed to describe the users of cyclo-oxygenase (COX)-2 inhibitors and traditional non-selective non-steroidal anti-inflammatory drugs (tNSAIDs). We report here the methodology, logistics and study design performances. Methods CADEUS is a cohort study designed to include 40000 patients randomly sampled monthly in the French National Healthcare Insurance database, who received at least one dispensation of celecoxib, rofecoxib or tNSAIDs (1: 1:2), from September 2003 to August 2004. Patients and prescribers were asked to fill a questionnaire on indication, medical history, risk factors and hospitalizations since drug acquisition. There was no reminder. For each respondent, healthcare resources used for the 6 months before and after inclusion were extracted from the database. Response rate, response delay, responders and non-responders characteristics were assessed. Results Of the 222 879 patients and their prescribers contacted, 20.8% patients and 32.6% prescribers responded. Median response delay was 16 days for patients and 17 days for physicians. Factors associated with patient response were age, cohort, type of prescriber and period of inclusion. Conclusion This is the first study of this design in France, combining data from a claims database and direct patient and prescriber questionnaires. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:571 / 580
页数:10
相关论文
共 29 条
[1]   Lessons from the withdrawal of rofecoxib - France has policy for overall assessment of public health impact of new drugs [J].
Abenhaim, L .
BRITISH MEDICAL JOURNAL, 2004, 329 (7478) :1342-1342
[2]   The withdrawal of rofecoxib [J].
Arellano, FM .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2005, 14 (03) :213-217
[3]   Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].
Bombardier, C ;
Laine, L ;
Reicin, A ;
Shapiro, D ;
Burgos-Vargas, R ;
Davis, B ;
Day, R ;
Ferraz, MB ;
Hawkey, CJ ;
Hochberg, MC ;
Kvien, TK ;
Schnitzer, TJ ;
Weaver, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528
[4]   Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs [J].
Cryer, B ;
Feldman, M .
AMERICAN JOURNAL OF MEDICINE, 1998, 104 (05) :413-421
[5]  
Czernichow S, 2001, REV EPIDEMIOL SANTE, V49, P93
[6]   Epidemiology, public health and medical cost databases [J].
Fender, P ;
Weill, A .
REVUE D EPIDEMIOLOGIE ET DE SANTE PUBLIQUE, 2004, 52 (02) :113-117
[7]   Celecoxib prescription:: Data from the "Securite Sociale" database of the Aquitaine region, south-western, France [J].
Fourrier-Réglat, A ;
de Bailliencourt, S ;
Molimard, M ;
Latry, P ;
Moore, N ;
Peter, C ;
Bégaud, B .
THERAPIE, 2005, 60 (01) :25-29
[8]   Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study [J].
Graham, DJ ;
Campen, D ;
Hui, R ;
Spence, M ;
Cheetham, C ;
Levy, G ;
Shoor, S ;
Graham, D .
LANCET, 2005, 365 (9458) :475-481
[9]   Increasing response to a postal survey of sedentary patients - a randomised controlled trial [ISRCTN45665423] [J].
Harrison, RA ;
Cock, D .
BMC HEALTH SERVICES RESEARCH, 2004, 4 (1)
[10]   Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis [J].
Hippisley-Cox, J ;
Coupland, C .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7504) :1366-1369